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John Sy1,2, Elani Streja1,2, Barbara Grimes3 and Kirsten L. Johansen4,5
1Division of Nephrology, Tibor Rubin Veterans Affairs Medical Center, Long Beach, California, USA; 2Division of Nephrology
and Hypertension, University of California, Irvine, Orange, California, USA; 3Division of Epidemiology and Biostatistics, Uni-
versity of California, San Francisco, San Francisco, California, USA; 4Division of Nephrology, University of California, San
Francisco, San Francisco, California, USA; and 5Nephrology Division, Hennepin County Medical Center, Minneapolis, Min-
nesota, USAIntroduction: Dialysis patients incur disproportionately high costs compared with other Medicare bene-
ficiaries. Care for frail individuals may be even more costly. We examined the extent to which frailty
contributes to higher costs among dialysis patients.
Methods: We used ACTIVE/ADIPOSE (A Cohort to Investigate the Value of Exercise/Analyses Designed to
Investigate the Paradox of Obesity and Survival in ESRD) enrollees (adult hemodialysis patients evaluated
from June 2009 to August 2011) in a retrospective cohort analysis. Individuals using Medicare as the
primary payer were included. Fried’s frailty phenotype was evaluated at baseline, 12, and 24 months.
Costs were derived from linkage with the US Renal Data System (USRDS) and Medicare claims data. We
used generalized estimating equations (GEEs) incorporating time-updated frailty and costs to evaluate
adjusted point estimates and the marginal cost associated with being frail. We also investigated if frail
patients who died during the study incurred higher costs than those who survived.
Results: Among 771 enrollees in ACTIVE/ADIPOSE, 425 met inclusion criteria. Mean age was 56  13
years, body mass index (BMI) 29.2  7.1 kg/m2, 42.4% were women, and 29.0% were frail at baseline. Over
a mean follow-up of 2.3 years, frail individuals incurred 22% (95% confidence interval [CI] 9.6%–35.8%)
higher costs compared with nonfrail individuals ($87,600 per patient per year [pppy], 95% CI 76,800–
100,000, vs. $71,800 pppy, 95% CI 64,800–79,600), the difference was driven primarily by higher inpatient
expenditures. The difference between frail and nonfrail patients’ inpatient expenditures was even more
pronounced among those who died during the study compared with those who survived.
Conclusions: Frail dialysis patients incur a significantly higher cost relative to their nonfrail counterparts,
primarily driven by higher inpatient costs. Frail patients near end of life incur even higher costs.
Kidney Int Rep (2020) 5, 289–295; https://doi.org/10.1016/j.ekir.2019.11.020
KEYWORDS: costs; dialysis; frailty; USRDS
Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).S ince 1972, millions of patients with end-stage renaldisease (ESRD) have been guaranteed Medicare
coverage, but the cost of caring for dialysis patients
has become a significant and growing burden to the
American health care system.1 Although ESRD benefi-
ciaries make up less than 1% of the Medicare popula-
tion, expenditures on this group totaled $35.4 billion
in 2016, accounting for roughly 7.2% of total Medicare
expenditures.1 The continued rise in Medicare ESRD
spending beyond inflation is driven primarily by thespondence: John Sy, Division of Nephrology, Tibor Rubin
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International Reports (2020) 5, 289–295increase in the number of patients covered,1 but the ag-
ing dialysis population and high prevalence of frailty
also could contribute. Frailty is highly prevalent
among patients on dialysis and may represent an addi-
tional economic burden to the health care system
beyond what would be expected based on ESRD alone.2
The cost of frailty has been assessed in nondialysis
populations, and studies have found that frail in-
dividuals incur a higher cost of care relative to their
nonfrail counterparts.2–5 Although these studies are
few, they are vital if we are to be able to assess the cost-
effectiveness of interventions intended to obviate poor
outcomes among frail patients. Given the dispropor-
tionate spending on ESRD beneficiaries, assessing the
incremental cost of frailty among medically complex
dialysis patients and ways to mitigate this cost may be
even more pertinent. This study seeks to quantify the289
CLINICAL RESEARCH J Sy et al.: Cost of Frailty Among Hemodialysis Patientsmarginal cost of frailty among a cohort of prevalent
dialysis patients by assessing differences in cost to
Medicare longitudinally and identifying drivers of this
cost difference.
METHODS
Study Design
We used data from the ACTIVE/ADIPOSE study, a
USRDS Special Study conducted by the Nutrition and
Rehabilitation/Quality of Life Special Studies Centers
that enrolled 771 prevalent in-center hemodialysis pa-
tients from the Atlanta and San Francisco Bay areas
between June 2009 and August 2011.6 Adult patients
($18 years of age) who were English or Spanish
speaking, on hemodialysis for at least 3 months, and
capable of providing informed consent were enrolled at
14 dialysis centers. Patients were excluded if they were
scheduled for living donor kidney transplantation or
planning to change to another dialysis center or to
peritoneal dialysis within the next 6 months. The study
was approved by the institutional review boards at the
University of California, San Francisco and Emory
University, and all patients provided written informed
consent. Patients were followed over the course of 2
years with study visits and assessments at baseline, 12
months, and 24 months.
Frailty
We used the Fried frailty phenotype, the most widely
used frailty measure among dialysis patients.7 Fried’s
frailty phenotype classifies individuals meeting 3 or
more of the following 5 criteria as frail8: weight loss,
exhaustion, low physical activity, weakness, and slow
gait speed.6,9 Weight loss was determined by asking
individuals if they had more than 10 pounds of unin-
tentional weight loss over the preceding 12 months.
Exhaustion was defined as having a positive response
to 2 questions regarding endurance and energy from
the Center for Epidemiologic Studies Depression ques-
tionnaire. Low physical activity was obtained using the
modified Minnesota Leisure Time Physical Activity
questionnaire. Grip strength was assessed using a
handheld dynamometer. Meeting the low gait speed
criterion was defined using the faster of two 15-foot
walking trials at an individual’s usual pace using
standard cut-points based on sex and height. Frailty
was assessed at baseline and at the 12-month and 24-
month follow-up study visits.
Defining the Time Period of Interest
We defined the time period during which we would
collect cost information as the period from the baseline
study visit until 12 months after the last measurement of
frailty (typically 36months from baseline study visit).We290only included periods during which patients were
enrolled in Medicare Parts A, B, or D with Medicare
serving as the primary payer (MPP) to obtain the most
comprehensive cost data available. Patientswere censored
at the time of death, transplant, or loss to follow-up.
Costs
Costs to Medicare were derived from claims data con-
tained in the Medicare Parts A, B, and D Standard
Analysis Files in the USRDS dataset using reported
Medicare payment amounts for each claim. Claims were
included if the beginning date of service was within
the time periods as previously defined. Annual time
periods after the date of enrollment were created
corresponding to frailty measurements (baseline to 12-
month follow-up visit, 12-month to 24-month follow-
up visit, 24-month to 36-month end of follow-up, or
the last date of frailty evaluation to the date of death,
transplantation, or loss to follow-up). Claims were
segregated into the appropriate time period by begin-
ning date of service. Costs were inflated to 2017 US
dollars by a discount rate of 3% per annum based on
the year of service. Costs were then aggregated during
the annual time period defined by frailty measurements
and converted to average US dollars per patient per
year (pppy) using the number of days on MPP for each
patient within each annual time period. For individuals
who died, received a transplant, or were lost to follow-
up, claims were normalized to annual time periods
based on the number of days from the last frailty
assessment to the date of death, transplant, or loss to
follow-up. Periods in which patients were not enrolled
in MPP were excluded (i.e., when patients lost or
switched coverage from MPP). Individual claims were
also identified as contributing to dialysis (outpatient
only), inpatient, outpatient (nondialysis), physician, or
medication costs based on the claims dataset from
which they were derived, or the location code associ-
ated with the claim.
Covariates
Other potential predictors of costs during follow-up
included age, race, sex, BMI, and comorbid condi-
tions (diabetes, congestive heart failure, and coronary
artery disease). Age, race, and sex were obtained by
patient report, and comorbidities were extracted from
the USRDS Medical Evidence file (Centers for Medicare
and Medicaid Services form 2728) and through chart
review at the baseline study visit.
Statistical Analysis
Comparisons between frail and nonfrail patients were
performed using either t-tests or Kruskal-Wallis tests
for continuous data and c2 tests for categorical data.Kidney International Reports (2020) 5, 289–295
Table 1. Baseline characteristics of participants by frailty status
Nonfrail Frail All P value
n 300 125 425
Age, yr 54.6  12.8 62.0  13.1 56.8  13.3 <0.001
Sex, % female 41.3 44.8 42.4 0.51
Body mass index, kg/m2 29.1  6.8 29.3  7.6 29.2  7.1 0.78
Albumin, mg/dl 4.03  0.33 3.87  0.42 3.98  0.36 <0.001
Race, % 0.89
White 14.7 16.8 15.3
Black 77.0 72.0 75.5
Other 8.3 11.2 9.2
Comorbidities, %
Diabetes 40.0 58.4 45.4 <0.001
Coronary artery disease 6.7 10.4 7.8 0.19
Congestive heart failure 14.7 19.2 16.0 0.25
Outcomes
Died in study, n (%) 29 (9.7) 28 (22.4) 57 (13.4) <0.001
J Sy et al.: Cost of Frailty Among Hemodialysis Patients CLINICAL RESEARCHTo account for the longitudinal nature of our time-
varying cost and time-varying frailty measurements,
we used a multivariable gamma-distributed GEE model
using a log link to assess the association between frailty
and total costs over time. GEE models are advantageous
over mixed-effect models given our population-level
approach with a relaxed distribution assumption for
model parameters.10,11 We used a gamma distribution
with a log link given our right-skewed cost distribu-
tion and a previous study using similar models.12 The
correlation structure was assumed to be exchangeable
for repeated observations. Once the GEE model was
fitted to our data, we extracted the marginal percent
difference in costs due to frailty from the beta estimate
for frail and nonfrail patients. We also estimated the
average total cost for frail and nonfrail patients stan-
dardized to the average age and BMI of our cohort. A
similar model was used to assess differences between
frail and nonfrail patients in dialysis costs, outpatient
costs, inpatient costs, physician costs, and medication
costs to investigate if any of these were drivers for
any observed cost differences between frail and
nonfrail patients. We performed a sensitivity analysis
assuming a zero rate of inflation to assess the impact
of inflation on our results. We also performed a
sensitivity analysis assessing the subset of individuals
who had claims from all 3 Medicare Parts (Parts A, B,
and D) to assess if patients having claims for only 1 or
2 parts (i.e., potentially only having coverage for
Medicare Parts A and B but not D) may introduce
bias.
We also hypothesized that patients who were near
end of life (i.e., died during the study) may have
contributed more expenditures on average compared
with patients who survived and that the higher cost
among frail patients might be driven in part by end-of-
life care. We evaluated and compared the baseline
characteristics of patients who died during the study
and those who did not die by using t-tests, Kruskal-
Wallis tests, and c2 tests, as appropriate. We then
investigated the differences in total and specific
(e.g., inpatient, outpatient) expenditures between
frail and nonfrail patients among those who died
and those who survived during the study using a
similar GEE model stratified by survival status. We
also assessed if there was an interaction between
frailty and death during the study with respect to
total cost.
Analyses were adjusted for age, sex, BMI, race, and
comorbidities (diabetes, coronary artery disease, and
congestive heart failure). No patients were missing data
on frailty, demographics, or comorbid conditions at
baseline. There were 19 patients missing information for
frailty at 12 months or 24 months (7 missing at 12 months,Kidney International Reports (2020) 5, 289–29514 missing at 24 months, 2 missing at both assessment
time periods, and 5 missing at 12 months but not 24
months). All analyses were performed using Stata,
version 14.2 (Stata Corp., College Station, TX).
RESULTS
Characteristics of the Cohort
Among 771 patients enrolled in the ACTIVE/ADIPOSE
study, 425 patients were identified to have Medicare
Part A, Part B, or Part D, or a combination thereof
during the study period. Of 425 patients included in
the study, 420 patients had Medicare Part A claims
during any point of the study period, 422 patients had
Medicare Part B claims during any point of the study
period, and 347 patients had Medicare Part D claims
during any point of the study period.
Patients in our cohort had a mean age of 56  13
years, a mean BMI of 29.2  7.1 kg/m2, 42.4% were
women, and 75.5% were black (Table 1). A total of 125
patients (29.4%) were considered frail at baseline. In
general, frail patients were older, had lower baseline
serum albumin concentrations, and were more likely to
have diabetes.
Marginal Cost of Frailty
We found that frail patients incurred 22.0% higher
costs compared with their nonfrail counterparts (95%
CI: 9.6%–35.8%) (Table 2). Frail patients incurred an
average of $87,600 pppy (95% CI: $76,800–$100,000
pppy) in expenditures compared with $71,800 pppy
(95% CI: $64,800–$79,600 pppy) for nonfrail patients
(costs standardized to average age and BMI of our
cohort). This translates to approximately $15,800 pppy
higher expenditures among frail patients compared
with nonfrail (95% CI: $12,000–$20,400 pppy).
When assessing individual contributions from dial-
ysis, outpatient (nondialysis), inpatient, physician, and291
Table 2. Adjusteda mean point estimates and percentage
differences in expenditures between frail and nonfrail patients
Nonfrail
31000 $/pppy
(95% CI)
Frail
31000 $/pppy
(95% CI)
Percentage difference
in expenditures
(95% CI)
Total costs 71.8 (64.8–79.6) 87.6 (76.8–100.0) þ22.0% (þ9.6 to þ35.8)
Dialysis 23.7 (21.8–25.6) 22.0 (19.9–24.4) 7.0% (14.9 to þ1.7)
Outpatient 11.4 (9.9–13.2) 14.3 (12.2–16.6) þ24.6% (þ7.8 to þ44.1)
Inpatient 18.4 (14.4–23.3) 29.9 (22.4–39.9) þ62.9% (þ27.3 to þ108.3)
Physician 9.2 (7.9–10.7) 10.3 (8.6–12.3) þ11.9% (1.8 to þ27.6)
Medication 7.8 (6.3–9.6) 8.0 (6.3–10.0) þ2.4% (8.4 to þ14.5)
CI, confidence interval.
aAdjusted for age, sex, body mass index, race, and comorbidities (diabetes, coronary
artery disease, and congestive heart failure).
Point estimates standardized to average age and body mass index of all study
participants.
Table 3. Baseline characteristics of patients who survived through
the study and died during the study
Survived Died All P value
n (%) 368 (87) 57 (13) 425
Age, yr 56.2  13.3 60.7  13.3 56.8  13.3 0.02
Sex, % female 41.6 47.4 42.3 0.41
Body mass index, kg/m2 29.3  7.1 28.5  7.1 29.2  7.1 0.44
Albumin, mg/dl 4.01  0.34 3.85  0.44 4.00  0.36 0.001
Pre-albumin, mg/dl 29.8  7.2 26.1  7.9 29.3  7.4 0.001
Race, % 0.47
White 14.7 –a 15.3
Black 76.1 75.5 75.5
Other 9.2 –a 9.2
Comorbidities, %
Diabetes 43.5 57.9 45.4 0.04
Coronary artery disease 7.6 –a 7.8 0.76
Congestive heart failure 15.8 17.5 16.0 0.73
Frail 26.4 49.1 29.4 <0.001
aPercentages suppressed because 1 or more categories contains <11 individuals.
CLINICAL RESEARCH J Sy et al.: Cost of Frailty Among Hemodialysis Patientsmedication claims, we found that frail patients incurred
higher outpatient and inpatient costs, but there was no
statistically significant difference in dialysis, physician,
or medication costs (Table 2). Outpatient and inpatient
costs were 24.6% (95% CI: 7.8%–44.1%) higher and
62.9% (95% CI: 27.3%–108.3%) higher, respectively,
among frail patients compared with nonfrail patients.
Average cost differences of $2900 pppy and $11,500
pppy were noted for outpatient and inpatient expendi-
tures, respectively, between frail and nonfrail patients.
In our sensitivity analysis assuming a zero rate of
inflation, we observed similarly higher costs incurred
by frail patients that remained driven by higher
inpatient and outpatient expenditures (data not
shown).
In our sensitivity analysis analyzing the 345 patients
who had claims for Medicare Parts A, B, and D, we
again observed a similar marginal cost of frailty driven
by higher inpatient and outpatient expenditures
(Supplementary Table 1).Marginal Cost of Frailty Among Those Who
Survived and Did Not Survive During Follow-up
Overall, 57 patients (13.4%) died during the study
period, 28 (49.1%) of whom were frail at baseline.
Patients who died were more likely to be older, have
lower serum albumin levels, lower serum pre-albumin
levels, more likely to have diabetes, and more likely
to be frail (Table 3).
Among survivors, frail and nonfrail patients
incurred approximately $74,200 pppy (95% CI:
$65,400–$84,200 pppy) and $67,800 pppy (95% CI:
$61,000–$75,300), respectively. The estimated marginal
cost of frailty among these survivors was $6400 pppy
(representing 9.4% higher costs), but the difference
was not statistically significant (95% CI: 1.4% lower to
21.6% higher) (Table 4).
Among individuals who died, frail and nonfrail
patients incurred approximately $181,300 pppy (95%292CI: $131,600–$240,800 pppy) and $135,300 pppy (95%
CI: $94,900–$192,800 pppy), respectively, with costs
34.0% higher on average among the frail patients
compared with their nonfrail counterparts (95% CI
2.6%–75.1% higher) (Table 4). We did not find any
statistically significant interaction between frailty and
death during the study on our total cost outcome (P
value for interaction ¼ 0.59), suggesting that although
cost of care was higher for patients who died, frail
patients continued to have higher costs independent of
survival.
Interestingly, the types of charges driving the
higher cost of care in frail and nonfrail patients
differed between survivors and nonsurvivors. Among
survivors, we saw statistically significantly higher
outpatient expenditures among frail versus their
nonfrail counterparts (27.0% higher, 95% CI: 9.2%–
47.9% higher), corresponding to an approximately
$3100 pppy difference. Among those who died, we
did not see any difference in outpatient expenditures,
but we noted that frail patients incurred 60.3%
higher inpatient expenditures (95% CI: 7.1%–140.1%
higher) with point estimates of $107,100 pppy and
$66,800 pppy for frail and nonfrail individuals,
respectively.DISCUSSION
Among our cohort of dialysis patients followed for up
to 3 years, we found that frail patients incurred 22%
higher costs compared with their nonfrail counter-
parts. Extrapolating to the overall US hemodialysis
population consisting of approximately 458,000
patients1 with the assumption that our observed
prevalence of frailty of approximately 29% extends to
the overall hemodialysis population, our study wouldKidney International Reports (2020) 5, 289–295
Table 4. Adjusteda mean point estimates and percentage
differences in expenditures between frail and nonfrail patients by
survival during study period
Nonfrail
31000 $/pppy
(95% CI)
Frail
31000 $/pppy
(95% CI)
Percentage difference in
expenditures between frail
and nonfrail (95% CI)
Survived through study period
Total costs 67.8 (61.0–75.3) 74.2 (65.4–84.2) þ9.4% (1.4 to þ21.6)
Dialysis 23.1 (21.2–25.2) 20.9 (18.7–23.4) 9.4% (18.0 to 0.0)
Outpatient 11.7 (10.0–13.5) 14.8 (12.6–17.4) þ27.0% (þ9.2 to þ47.9)
Inpatient 15.8 (12.3–20.4) 20.6 (15.0–28.3) þ30.4% (1.3 to þ72.2)
Physician 8.4 (7.0–10.1) 8.5 (7.0–10.3) þ0.8% (12.3 to þ15.9)
Medication 7.9 (6.3–9.9) 7.9 (6.2–10.0) þ0.1% (9.6 to þ10.9)
Died during study period
Total costs 135.3 (94.9–192.8) 181.3 (136.6–240.8) þ34.0% (þ2.6 to þ75.1)
Dialysis 31.1 (27.1–35.7) 27.7 (23.1–33.2) 10.9% (24.5 to þ5.2)
Outpatient 7.7 (4.7–12.7) 9.2 (5.7–14.8) þ19.8% (24.6 to þ90.4)
Inpatient 66.8 (37.2–120.0) 107.1 (68.0–168.8) þ60.3% (þ7.1 to þ140.1)
Physician 18.9 (13.6–26.2) 23.6 (17.6–31.7) þ25.1% (3.5 to þ62.2)
Medication 7.1 (3.5–14.5) 8.0 (4.4–14.7) þ12.6% (38.9 to þ107.6)
CI, confidence interval.
aAdjusted for age, sex, body mass index, race, and comorbidities (diabetes, coronary
artery disease, and congestive heart failure).
Point estimates standardized to average age and body mass index of all study
participants.
J Sy et al.: Cost of Frailty Among Hemodialysis Patients CLINICAL RESEARCHsuggest that frailty may be associated with approxi-
mately $2.2 billion in excess US health care expendi-
tures annually. The additional costs incurred by frail
patients was largely driven by higher expenditures
on inpatient and outpatient services, although
inpatient services accounted for a larger proportion
of spending compared with outpatient services. In
fact, inpatient expenditures incurred by frail hemo-
dialysis patients are estimated to contribute an
additional $1.6 billion annually, whereas outpatient
expenditures contribute only an additional $400
million annually.
Given that frail patients are at higher risk of death,
we hypothesized that end-of-life care might account for
a substantial amount of the excess costs among frail
patients. Indeed, individuals who died incurred more
than double the pppy costs compared with individualsTable 5. Studies comparing cost of frail versus nonfrail patients defined
Study Country Population
Frailty
prevalence,
%
Sirven and Rapp,
201613
France 1284 Community-dwelling elders aged $65 13.0
Bock et al.,
20162
Germany 2598 Community-dwelling adults aged 57–84 8.0
García-Nogueras
et al., 201714
Spain 830 Community-dwelling adults age $ 70 19.3
Hajek et al.,
20173
Germany 1636 Community-dwelling adults aged 57–84 6.2–12.0
Goldfarb et al.,
201715
Canada 235 patients age $60 undergoing cardiac surgery in
Montreal, Canada
38.7
Ensrud et al.,
201812
United
States
2150 community-dwelling women participating in the
Study of Osteoporotic Fractures (SOF) year 10
19.0
Kidney International Reports (2020) 5, 289–295who did not die during follow-up, which may be
attributable to more hospitalizations or to more
expensive hospitalizations (e.g., with more procedures
and intensive care) closer to the end of life. However,
there was no statistically significant interaction be-
tween frailty and survival status, suggesting that frail
patients incurred higher costs independent of survival
status. Our analysis suggests that although more money
is spent toward the end of life, especially on inpatient
care, frail patients remain more expensive even after
accounting for these costs.
Although there have been several studies in recent
years assessing the cost of frailty, all but 1 study
investigated costs within a 12-month period, and none
examined the cost of care in a medically complex
dialysis population (Table 52,3,12–15). Studies have
either investigated costs incurred among community-
dwelling adults whose prevalence of frailty ranges
from 6% to 13%,2,3,12–14 or reported peri-surgical costs
in a sicker population with a prevalence of frailty of
38.7%.15 All have shown higher costs among frail in-
dividuals regardless of the length of follow-up time or
the prevalence of frailty.2,5,12–15 Compared with these
studies, our study highlights the magnitude of Medi-
care expenditures for the ESRD benefit program (which
were at least 3 to 4 times higher among ESRD patients
compared with community-dwelling frail elders), the
high prevalence of frailty among patients on dialysis,
and the association of frailty with higher cost even in
this already-high-cost population. The difference in the
mean cost of care for frail compared with nonfrail
dialysis patients was considerably larger than the dif-
ference between frail and nonfrail community-dwelling
elders in most studies.
Given the magnitude of health care utilization
among patients on dialysis, cost savings may be real-
ized with even small decreases in utilization. Main-
taining patients in or returning them to a nonfrail state
could potentially save money and decrease mortality.using Fried’s frailty phenotype
Cost assessment and follow-up period Cost difference between frail and nonfrail
12-month ambulatory health care
expenditures for 2012
EUR 3900 vs. EUR 2629
Self-reported health care use over a
retrospective 3 months
EUR 3659 (4–5 criteria), EUR 1616 (3
criteria), and EUR 642 (nonfrail)
Associated costs related to diagnosis-related
group over 1044 days of follow-up
EUR 2476 vs. EUR 1217
Self-reported health care use over a
retrospective 3 months
Cost increase by 54%–101%
Costs from operation date to date of discharge
based on diagnosis-related groups
CAD 32,742 vs. CAD 23,370
12-months following Year 10 examination in
the SOF study
USD 10,755 vs. USD 3781
293
CLINICAL RESEARCH J Sy et al.: Cost of Frailty Among Hemodialysis PatientsInterventions to prevent frailty and improve the health
of frail dialysis patients, especially aimed at decreasing
rates of hospitalizations, are urgently needed given the
rapid rise of health care expenditures. Indeed, cost
savings could be higher than we estimated, considering
the indirect costs of caring for frail patients, including
the cost of caregivers and costs related to the inability
to work, which likely far exceed the calculated direct
costs of care to the Medicare program.
Our well-defined prospective cohort of patients on
dialysis who were followed over the course of 2 years
with annual frailty assessments and corresponding
Medicare claims data over 3 years is a strength. We
used repeated measurements of costs and frailty to
avoid dependence on a single determination of frailty
during several years of follow-up, which is especially
important given that the state of frailty can change and
that change in frailty status in turn may affect health
care expenditures. A limitation of our study is the
modest sample size; however, health care expenditures
in our study were similar to national data (approxi-
mately $88,000 pppy),1 suggesting that our cohort’s
health care utilization was representative of the popu-
lation as a whole. We did not assess temporal trends in
expenditures, given our rolling enrollment and rela-
tively short follow-up time of 3 years. To partially
account for differences in claim year, we adjusted all
costs for inflation and performed a sensitivity analysis
assuming a zero rate of inflation. Adjusting for inflation
did not significantly alter our overall results, suggest-
ing our results are robust. We are also unable to fully
account for the transition to the ESRD Prospective
Payment System between 2009 and 2011; however, our
intent was to analyze direct costs to Medicare
(excluding costs incurred by patients), and we antici-
pate that the claims data continue to reflect payment
from Medicare to facilities and providers. Another
limitation to this study is that not all patients used
MPP for the entire study period, and we extrapolated
for patients who switched coverage, lost coverage, or
gained coverage within a calendar year. Our focus on
patients using MPP was necessary to ensure that we
captured all medical claims, which could have affected
external validity. However, good alignment of costs in
our cohort with costs in the overall US dialysis popu-
lation1 and the large percentage of dialysis patients for
whom Medicare is the primary payer support the val-
idity of our findings. Last, although we selected
covariates that may be confounders to the association
between frailty and costs, there may be residual con-
founding from factors that were not measured or
accounted for.
In conclusion, frail patients on dialysis incur
significantly higher costs compared with their nonfrail294counterparts over time. The cost difference between
frail and nonfrail patients appears to be driven by
significantly higher inpatient expenditures, especially
among patients who died during study follow-up.
Death during follow-up was associated with higher
costs for both frail and nonfrail patients compared with
those who survived. Improving or maintaining a
nonfrail status to decrease hospitalizations may help to
decrease Medicare spending.DISCLOSURE
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